Chicago's Sparx Therapeutics to Build Biologics Manufacturing Facility in China
publication date: Jul 8, 2021
Sparx Therapeutics, a Chicago antibody drug conjugate (ADC) company, will build a 1.2 million square-foot manufacturing facility in Yangzhou, which is west of Shanghai. Sparx uses AI to drive its proprietary target mining platform, identifying cellular targets that offer optimal and synergistic biological activity. The targets are refined by the company's multi-component Sailing™ antibody optimization system and four cutting-edge ADC technologies to improve the success rate. Dr. Gui-Dong Zhu, the CEO of Sparx, has signed a 20-year lease agreement for the facility with Yangzhou Economic Zone. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.